Upgrade to SI Premium - Free Trial

Form 3 Nano-X Imaging Ltd. For: Mar 18 Filed by: Suesskind Dan S

April 30, 2026 2:32 PM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Suesskind Dan S
(Last) (First) (Middle)
C/O NANO-X IMAGING LTD., OFER TECH PARK
94 SHLOMO SHMELTZER ROAD
(Street)
PETACH TIKVA 4970602
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026 		3. Issuer Name and Ticker or Trading Symbol
Nano-X Imaging Ltd. [ NNOX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares (1) 7,792
D
Ordinary shares (2) 17,544
D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy ordinary shares) (3) 02/09/2031 Ordinary shares 12,505 64.61 D
Stock Option (right to buy ordinary shares) (4) 12/28/2032 Ordinary shares 50,000 17.63 D
Stock Option (right to buy ordinary shares) (5) 12/31/2033 Ordinary shares 10,000 11.52 D
Explanation of Responses:
1. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on December 10, 2024 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2027) all underlying shares will be issued to the Reporting Person.
2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on December 10, 2025 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2028) all underlying shares will be issued to the Reporting Person.
3. The options reported in this row were granted to the Reporting Person by the Issuer on February 9, 2021 and are fully vested and exercisable as of the date of this report.
4. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., May 16, 2022), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (May 16, 2026).
5. The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (August 14, 2027).
Remarks:
Exhibit 24.1 Power of Attorney
/s/ Marina Gofman Feler, attorney-in-fact 04/30/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

ATTACHMENTS / EXHIBITS

POWER OF ATTORNEY

Categories

SEC Filings